Skip to main content

REVIEW article

Front. Neurosci.
Sec. Neurodegeneration
Volume 18 - 2024 | doi: 10.3389/fnins.2024.1488382
This article is part of the Research Topic Myeloid Cells as Active Players in Human Neurodegenerative Diseases View all 3 articles

Myeloid Antigen-Presenting Cells in Neurodegenerative Diseases: A focus on Classical and Non-Classical MHC Molecules

Provisionally accepted
  • Indiana University School of Medicine, Indianapolis, Indianapolis, Indiana, United States

The final, formatted version of the article will be published soon.

    In recent years, increasing evidence has highlighted the critical role of myeloid cells, specifically those that present antigen (APCs) in health and disease. These shape the progression and development of neurodegenerative disorders, where considerable interplay between the immune system and neurons influences the course of disease pathogenesis. Antigen-presenting myeloid cells display different classes of major histocompatibility complex (MHC) and MHC-like proteins on their surface for presenting various types of antigens to a wide variety of T cells. While most studies focus on the role of myeloid MHC class I and II molecules in health and disease, there is still much that remains unknown about non-polymorphic MHC-like molecules such as CD1d and MR1. Thus, in this review, we will summarize the recent findings regarding the contributions of both classical and non-classical MHC molecules, particularly on myeloid microglial APCs, in neurodegenerative diseases. This will offer a better understanding of altered mechanisms that may pave the way for the development of novel therapeutic strategies targeting immune cell-MHC interactions, to mitigate neurodegeneration and its associated pathology.

    Keywords: Myeloid Cells-Microglia-MHC-MR1-CD1d-neurodegenerative diseases Aβ, Amyloid Beta α-Galcer, α-Galactosylceramide AD, Alzheimer's Disease ADRD, Alzheimer's Disease and Related Dementias ALS, Amyotrophic Lateral Sclerosis APC, Antigen-Presenting Cells BBB, Blood-Brain Barrier CD1d

    Received: 29 Aug 2024; Accepted: 20 Nov 2024.

    Copyright: © 2024 Afify, Lipsius, Johnson and Brutkiewicz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Randy Brutkiewicz, Indiana University School of Medicine, Indianapolis, Indianapolis, Indiana, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.